Targets to Therapies: Aggregation and Synuclein Biology Target Validation supports researchers validating targets in aggregation and synuclein biology to guide therapeutic decisions for Parkinson’s disease.
Targets to Therapies: Mitochondrial Target Validation supports researchers studying mitochondrial targets to build evidence that guides therapeutic decisions for Parkinson’s disease.
Parkinson's Disease Biomarker Innovation and Advancement Program supports teams developing fluid- and imaging-based biomarkers for clinical implementation and broader use in Parkinson's research.
The Parkinson's Foundation Impact Awards fund bold research to advance understanding of Parkinson’s disease biology or accelerate new interventions.
In-vitro models & assays to identify novel therapies for neuroinflammatory diseases supports researchers developing human-centered models and assays to discover and optimize small-molecule treatments.
Accelerating Drug Discovery for Frontotemporal Degeneration supports researchers and clinicians developing small molecules and biologics to advance disease-modifying treatments for frontotemporal dementia.